Sign in Subscribe
Cancer treatment

Nonspecific Immunotherapy Shows Promise in Treating Cancer

Strategic Insights

— 1 min read

Scientists in the United States have reported new findings in the field of cancer research, revealing that nonspecific immunotherapy using intratumoral lipopolysaccharide and zymosan A, but not GM-CSF, is effective in generating an anti-tumor response in subcutaneous RG-2 gliomas. This treatment approach may be useful in generating an anti-tumor response for a variety of cancers and could potentially work synergistically with currently available cytotoxic therapies. In a study published in the Journal of Neuro-Oncology, researchers examined the response of syngeneic rat gliomas to treatment with several nonspecific stimulators of dendritic cells and macrophages alone or in combination with radiation therapy.

Key Takeaways:

  • The study found that intratumoral lipopolysaccharide (LPS) and zymosan A (ZymA) delayed tumor growth in 71% and 50% of animals, respectively, and led to complete tumor regression in 71% (LPS) and 50% (ZymA) of animals.
  • Multiple doses of LPS and ZymA were superior to single doses, and combination treatment with IT LPS and zymosan A and single-fraction external beam radiotherapy (EBRT) showed a synergistic effect in delaying tumor growth.
  • GM-CSF showed no anti-tumor effects in this study, indicating that it may not be a suitable treatment option for RG-2 gliomas.
  • The study suggests that direct IT treatment with TLR ligands LPS and ZymA are effective in generating an anti-tumor response and may require T cells for a successful outcome.
  • The researchers concluded that these treatments may synergize with cytotoxic therapies such as EBRT.

Statistics:

  • 71% of animals showed complete tumor regression after treatment with high doses of LPS.
  • 50% of animals showed complete tumor regression after treatment with high doses of ZymA.
  • 100% of animals showed delayed tumor growth after combination treatment with IT LPS and EBRT.
  • 0% of animals showed anti-tumor effects after treatment with GM-CSF alone.

Sources:

  • Mariani, C.L. et al. (2007). Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas. Journal of Neuro-Oncology, 85(3), 231-240.
  • Mariani, C.L. (Interview). University of Florida, McKnight Brain Institute, Department of Neuroscience, College of Medicine, Gainesville, FL, USA.
  • Kluwer Academic Publ. (Publisher). Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.

Read more